Plitican

Plitican is an early-stage biotechnology company focused on the development of next-generation T-cell receptor (TCR) therapies for the treatment of solid tumors. The company leverages advanced T-cell engineering technologies to identify and target specific antigens expressed by cancer cells, aiming to overcome the limitations of current immunotherapies in the solid tumor microenvironment. Founded by pioneers in the field of adoptive cell therapy, Plitican is building a proprietary platform to enhance the persistence and potency of engineered T cells. The company's research is centered on creating highly specific TCR-T cell products that can effectively infiltrate and eradicate aggressive malignancies. Plitican operates primarily in the pre-clinical stage, advancing its pipeline toward initial human clinical trials.